The DOI matches its Crossref record.
A review of bullous pemphigoid associated with PD‐1 and PD‐L1 inhibitors
Abstract
Background: Dermatologic toxicity represents a substantial portion of all immune‐related adverse events (ir AE s) associated with PD‐1/PD‐L1 inhibitors. Bullous pemphigoid (BP) is a rare cutaneous side effect of these medications, which can initially be clinically indistinguishable from other, low‐grade cutaneous toxicity. Objective: To better characterize the clinical features of BP associated with PD‐1/PD‐L1 inhibitors, evaluate the efficacy of various treatment regimens, determine the frequency of prodromal pruritus, and assess whether immunological diagnostic studies for BP are warranted in patients treated with checkpoint inhibitors who develop intractable pruritus. Methods: A comprehensive review of the English‐language medical literature was performed using key terms. Papers published on any date and from all origins were considered. Fourteen publications, containing 21 patient cases, were selected independently by two reviewers and deemed relevant to the present publication. Results: Pruritus was a prominent feature of the majority (12/21) of cases and preceded or occurred concurrently with BP development. Bullae developed within 6–8 months of initiation of PD‐1/PD‐L1 inhibitors; however, a smaller subset of patients did not develop bullae for 1–1.5 years following initiation of therapy. Mean time to pruritus was similar for pembrolizumab and nivolumab at 19 and 21 weeks, respectively. Development of BP required discontinuation of immunotherapy in 76% (16/21) of cases. Conclusion: Prodromal or “non‐bullous” variants of BP must be considered in patients treated with checkpoint inhibitors who develop protracted or worsening pruritus. Early diagnostic immunological evaluation of the skin may lead to improved patient outcomes by facilitating timely initiation of treatment and prevent disruptions in cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Immune checkpoint inhibitor–related dermatologic adverse events
Geisler, A. N., Phillips, G. S., Barrios, D. M., Wu, J., Leung, D. Y. M., Moy, A. P., Kern, J. A., & Lacouture, M. E. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.03.132 · Cited by 480
Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls
Darnell, E. P., Mooradian, M. J., Baruch, E. N., Yilmaz, M., & Reynolds, K. L. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-0897-9 · Cited by 380
Hoefsmit, E. P., Rozeman, E. A., Haanen, J. B. A. G., & Blank, C. U. (2019) · ESMO Open · doi:10.1136/esmoopen-2018-000472 · Cited by 29
Metadata
- Authors
- Lopez, A. T., Khanna, T., Antonov, N., Audrey‐Bayan, C., & Geskin, L.
- Venue
- International Journal of Dermatology
- Publisher
- Wiley
- Published
- 2018-04-06
- Volume
- 57
- Issue
- 6
- Pages
- 664-669
- ISSN
- 0011-9059 (ISSN-L)
- 1365-4632
- OpenAlex
- W2798119945
- Cited by
- 171
- References
- 0
- FWCI
- 13.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.